Investigating the Effect of the Non-nutritive Sweetener Sucralose in Inflammatory Bowel Disease
Start Date
4/18/2024
Completion Date
6/1/2027
Summary
This study will focus on the commonly used non-nutritive sweetener (NNS) sucralose (2 sachets/day resulting in daily dose: sucralose 2.5mg/kg) and its role in changing the gut microbiota in humans with Inflammatory Bowel Disease (IBD), compared to healthy non-IBD individuals. We will focus on studying IBD patients affected with Crohn's Disease (CD) as a proof of principle that could be tested later in other IBD subtypes (ulcerative colitis or others specific surgical conditions).
Detailed Description
Participation in this study will last for a minimum of 35 days (Phase I: 14-days; baseline with removal of all NNS (eg saccharin, sucralose, steviosides, aspartame, acesulfame-k, erythritol) from the diet, Phase II: 21-days; sucralose intervention, and will involve one virtual visit (study visit 1) and two in-person study visits (study visit 2 and study visit 3). Fecal \& urine samples will be collected before/after each phase. Blood will also be collected.
Eligibility Criteria
Age Range: 18 years to 75 years
Interventions
Sucralose (non-nutritive sweetener)
Conditions
Locations
UH Minoff Health Center
Chagrin Falls, Ohio 44122
United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio 44106
United States
UH Westlake Health Center
Westlake, Ohio 44145
United States